Background Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril‐valsartan has been
recommended as one of the first‐line therapies in heart failure with reduced ejection fraction …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Background Sacubitril–valsartan has been widely reported for reducing the risk of
cardiovascular death and improving left ventricular remodeling in patients with heart failure …

The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …

Aims In patients at high risk of heart failure following myocardial infarction (MI) as a result of
residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor neprilysin …

Background Compared to angiotensin inhibition, angiotensin-neprilysin “blockade”
improves mortality and reduces hospitalizations in patients with heart failure (HF) with …

Objective: To systematically review the efficacy and safety of sacubitril-valsartan in the
treatment of acute myocardial infarction complicated with heart failure and to observe …

Objective The aim of this study was to investigate the effect of sacubitril/valsartan (Sal/Val)
on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute …

Aims Although clinical guidelines advocate the use of the highest tolerated dose of
angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers after acute …

Abstract Background: Sacubitril/valsartan (SAC/VAL) is approved by the US Food and Drug
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …